Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Cipla
Teva
Queensland Health
Boehringer Ingelheim
QuintilesIMS
Federal Trade Commission
Cerilliant

Generated: December 13, 2018

DrugPatentWatch Database Preview

Litigation Details for ELI LILLY AND COMPANY v. TEVA PARENTERAL MEDICINES, INC. (S.D. Ind. 2010)

« Back to Dashboard

ELI LILLY AND COMPANY v. TEVA PARENTERAL MEDICINES, INC. (S.D. Ind. 2010)

Docket ➤ Try a Free Trial Date Filed 2010-10-29
Court District Court, S.D. Indiana Date Terminated 2015-08-25
Cause 35:271 Patent Infringement Assigned To Tanya Walton Pratt
Jury Demand None Referred To Denise K. Larue
Parties APP PHARMACEUTICALS, LLC; BARR LABORATORIES, INC.; ELI LILLY AND COMPANY; FRESENIUS KABI USA, LLC; PLIVA HRVATSKA D.O.O.; TEVA PARENTERAL MEDICINES, INC.; TEVA PHARMACEUTICALS USA INC.
Patents 10,046,000; 4,314,081; 5,217,974; 5,344,932; 5,424,286; 5,658,590; 7,470,506; 7,772,209
Attorneys Andrew V. Trask; Anne N. DePrez; Brian J. Prew; Daryl L. Wiesen; Elaine Herrmann Blais; Emily L. Rapalino; Jan M. Carroll; Kandi Kilkelly Hidde; Megan A. Hughes; Michael B. Cottler; Natasha E. Daughtrey
Firms Barnes & Thornburg LLP; Goodwin Procter LLP; Goodwin Procter LLP, the New York Times Building
Link to Docket External link to docket
Small Molecule Drugs cited in ELI LILLY AND COMPANY v. TEVA PARENTERAL MEDICINES, INC.
Biologic Drugs cited in ELI LILLY AND COMPANY v. TEVA PARENTERAL MEDICINES, INC.
The biologic drug covered by the patents cited in this case is ➤ Try a Free Trial .

Details for ELI LILLY AND COMPANY v. TEVA PARENTERAL MEDICINES, INC. (S.D. Ind. 2010)

Date Filed Document No. Description Snippet Link To Document
2010-10-29 1 expiration of U.S. Patent No. 5,344,932 (“the ’932 patent”). The expiration date of the ’932 patent is earlier…ACTION 1. This is an action for patent infringement under the patent laws of the United States, Title… by the FDA. 20. United States Patent N0.7,772,209 (“the ’209 patent”), entitled “Novel Antifolate Combination…The ’209 patent is attached as Exhibit A hereto. n 21. Lilly is the assignee of the ’209 patent. As set… greater detail in the ’209 patent, one or more claims of the ’209 patent, incorporated by reference herein External link to document
2012-09-25 142 of U.S. Patent No. 5,344,932 (“the ’932 patent”). The expiration date of the ’932 patent is earlier… 1. This is an action for patent infringement under the patent laws of the United States, Title… 21. United States Patent No.7,772,209 (“the ’209 patent”), entitled “Novel Antifolate…assignee of the ’209 patent. As set forth in greater detail in the ’209 patent, one or more claims …certification for the ’209 patent is an act of infringement of the ’209 patent. 30. External link to document
2013-06-14 241 161:2-7 Tape 3_00:10:29-41; 00:10:46 – 00:11:15; …2010 25 August 2015 1:10-cv-01376 830 Patent None District Court, S.D. Indiana External link to document
2013-06-14 250 United States Patent Number 7,772,209, # 2 Exhibit 4 - United States Patent Number 5,217,974, # 3 Exhibit…Exhibit 6 - United States Patent Number 5,563,126, # 4 Exhibit 10 - European Patent Number 0 595 005 (A1),… TRIAL BRIEF Regarding The Invalidity of U.S. Patent No. 7,772,209 by All Defendants. (Attachments: … 2013 regarding the assertion of claims of U.S. Patent 7,772,209+A13)(Hidde, Kandi) (Entered: 06/14/2013…2010 25 August 2015 1:10-cv-01376 830 Patent None District Court, S.D. Indiana External link to document
2013-07-29 285 pemetrexed disodium, and U.S. Patent No. 5,217,974 (the “’974 patent”) claiming, inter alia, a method…pleural mesothelioma. U.S. Patent No. 7,772,209 (the “’209 patent” or “patent-in-suit”) covers the administration…earlier Lilly patents relevant to pemetrexed, U.S. Patent No. 5,344,932 (the “’932 patent”) for the compound… ’209 patent-in-suit in August 2010. Lilly sued Defendants for infringement of the ’209 patent after…expiration of the ’209 patent. Defendants contend that the asserted claims of ’209 patent are obvious under External link to document
2013-07-31 289 Trial Brief Regarding the Invalidity of U.S. Patent No. 7,772,209, filed by Defendants APP PHARMACEUTICALS…2010 25 August 2015 1:10-cv-01376 830 Patent None District Court, S.D. Indiana External link to document
2014-03-31 336 , Lilly obtained U.S. Patent No. 5,217,974 (the “‘974 Patent”). The ‘974 Patent claimed the use of folic…the U.S. Patent No. 7,772,209 (the “‘209 Patent”). The ‘209 Patent is a method-of-use-patent which covers…Zagreb, Croatia. B. The Patent-In-Suit The patent-in-suit U.S. Patent No. 7,772,209, was issued…claims in a second patent not patentably distinct from the claims of the first patent.’” Eli Lilly &…the ‘209 Patent are obvious variants of claim 20 of the ‘974 Patent. Claim 20 of the ‘974 Patent claims External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Express Scripts
AstraZeneca
McKinsey
Dow
Citi
Mallinckrodt
McKesson
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.